×
About 28,273 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  9,673 results

Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunctio...
https://doi.org/10.1080/16078454.2022.2026018
Hematology (Amsterdam, Netherlands); Kongkiatkamon S, Chintabanyat A et. al.

Jan 25th, 2022 - Fertility is a concern in young female survivors of hematological malignancies. We evaluated post-treatment ovarian function in patients by measuring anti-Müllerian hormone (AMH) and conventional hormone levels to correlate with menstruation and f...

What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute My...
https://doi.org/10.1097/PPO.0000000000000569 10.3324/haematol.2020.259531 10.1200/JCO.2019.37.15_suppl.7034
Cancer Journal (Sudbury, Mass.); Wang C, Sallman DA

Jan 25th, 2022 - TP53 is a key tumor suppressor gene involved in fundamental biological processes of genomic stability and is recurrently mutated in a subgroup of myelodysplastic syndromes and acute myeloid leukemia. These patients have unique clinical and molecul...

The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted...
https://doi.org/10.1097/PPO.0000000000000575 10.1182/blood.2021013626 10.1016/s1470-2045(12)70349-2
Cancer Journal (Sudbury, Mass.); Kinsella F, Craddock C

Jan 25th, 2022 - Allogeneic stem cell transplantation (allo-SCT) is an increasingly important treatment strategy in fit adults with acute myeloid leukemia (AML). Increased donor availability and a steady reduction in transplant-related mortality (TRM) over the las...

Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Mye...
https://doi.org/10.1097/PPO.0000000000000576
Cancer Journal (Sudbury, Mass.); Perl AE, Pratz KW

Jan 25th, 2022 - Therapeutic outcomes for acute myeloid leukemia patients with Fms-like tyrosine kinase 3 (FLT3) mutations have improved substantially since the discovery of small molecule tyrosine kinase inhibitors. Today, use of FLT3 inhibitors is standard in fr...

Comparison of early mortality between leukapheresis and non-leukapheresis in adult acut...
https://doi.org/10.1080/16078454.2021.2024939
Hematology (Amsterdam, Netherlands); Rinaldi I, Sutandyo N et. al.

Jan 25th, 2022 - One of the treatment modalities that can be used for hyperleukocytosis is leukapheresis. However, the result of studies showing the benefit of early mortality through the use of leukapheresis versus no leukapheresis is still inconclusive. Hence, w...

see more →

Guidelines  11 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  29 results see all →

Clinicaltrials.gov  537 results

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT03586609

Jan 21st, 2022 - PRIMARY OBJECTIVE: I. To assess the complete response (CR/complete response with incomplete recovery [CRi]) rate of patients with acute myeloid leukemia (AML) treated with venetoclax combined with cladribine (2-CDA) plus low-dose cytarabine (LDAC)...

Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
https://clinicaltrials.gov/ct2/show/NCT02773732

Jan 21st, 2022 - This study will look at: any side effects that occur, the effectiveness of the study drug, and how your disease reacts to ciprofloxacin in combination with etoposide. This study will try to find the highest tolerated dose of ciprofloxacin without ...

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
https://clinicaltrials.gov/ct2/show/NCT05010122

Jan 21st, 2022 - PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) of the combination of decitabine and cedazuridine (ASTX727), venetoclax and gilteritinib in patients with relapsed/refractory FLT3- mutated acute myeloid leukemia (AML) or high-r...

BMS-986253 in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05148234

Jan 21st, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04813263

Jan 20th, 2022 - Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections) and is the most common acute leukemia in adults. This study will assess how safe and effective oral venetoclax ...

see more →

News  1,057 results

Rapid Readout: AGILE: ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation
https://www.onclive.com/view/agile-ivosidenib-azacitidine-versus-placebo-azacitidine-in-patients-with-newly-diagnosed-acute-myeloid-leukemia-with-an-idh1-mutation

Jan 17th, 2022 - OncLive® Rapid Readout from AGILE: ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation Segment Description: Pau Montesinos, MD, PhD, discusses the AGILE phase 3 cli...

Novel Immunotherapy Combos Target TIM-3 and PD-1/PD-L1 Networks
https://www.onclive.com/view/novel-immunotherapy-combos-target-tim-3-and-pd-1-pd-l1-networks

Jan 10th, 2022 - The immune checkpoint TIM-3 is shaping up to be a viable target for designing therapies for patients with non–small cell lung cancer (NSCLC) and other malignancies, according to a growing body of early scientific and clinical data. Investigative e...

Dr. Matthews on the Efficacy of CPX-351 Vs Venetoclax/Azacitidine in AML
https://www.onclive.com/view/dr-matthews-on-the-efficacy-of-cpx-351-vs-venetoclax-azacitidine-in-aml

Jan 7th, 2022 - Andrew Matthews, MD, fellow, Division of Hematology and Oncology, Department of Medicine, Penn Medicine, discusses the efficacy of CPX-351 (daunorubicin and cytarabine; Vyxeos) vs venetoclax (Venclexta) plus azacitidine (Vidaza) in acute myeloid l...

Orca-T Shows Impressive Clinical Outcomes in High-Risk Hematological Cancers
https://www.onclive.com/view/orca-t-shows-impressive-clinical-outcomes-in-high-risk-hematological-cancers

Jan 4th, 2022 - The high-precision allogeneic cellular therapy Orca-T significantly improved graft-vs-host disease (GVHD)–free relapse-free survival (RFS) and time to engraftment, significantly reduced acute and chronic GVHD, and showed a trend toward improved ov...

Investigator Looks to Novel Therapy to Advance TP53-Mutant MDS Landscape
https://www.onclive.com/view/investigator-looks-to-novel-therapy-to-advance-tp53-mutant-mds-landscape

Jan 3rd, 2022 - The small molecular eprenetopopt (APR-246) is showing promising efficacy in patients with TP53-mutant myelodysplastic syndromes (MDS), a distinct molecular subgroup associated with poor outcomes, for which therapies have been unsuccessful in impro...

see more →

Patient Education  2 results see all →